Bio­cy­to­gen se­cures $65M Se­ries C fund­ing

BioSpectrum (Asia) - - Finance News -

CMB In­ter­na­tional Cap­i­tal Cor­po­ra­tion Ltd, a wholly-owned sub­sidiary of China Mer­chants Bank, re­cently led a $65 mil­lion se­ries C round in Bei­jing Bio­cy­to­gen Co., Ltd., a gene tar­geted an­i­mal model and ser­vice sup­plier. Ex­ist­ing in­vestors in­clud­ing SDIC Ven­ture Cap­i­tal Man­age­ment, 3E Bioven­tures, Cowin Cap­i­tal, Oriza Hold­ings, also par­tic­i­pated in the round, ac­cord­ing to the com­pany’s of­fi­cial WeChat ac­count.

Bio­cy­to­gen’s cus­tomers in­clude aca­demic in­sti­tu­tions such as Har­vard Uni­ver­sity, Uni­ver­sity of Tokyo, Uni­ver­sity of Oxford, Pek­ing Uni­ver­sity, Ts­inghua Uni­ver­sity, and hos­pi­tals, such as Mas­sachusetts Gen­eral Hos­pi­tal, Union Hos­pi­tal, Pek­ing Uni­ver­sity Hos­pi­tal, as well as in­ter­na­tional com­pa­nies such as Johnson and Johnson, Roche, GSK and Merck. The com­pany was founded in 2009 by Dr Yuelei Shenm, a Uni­ver­sity of Mas­sachusetts School of Medicine grad­u­ate with 20 years of ex­pe­ri­ence in im­munol­ogy, molec­u­lar bi­ol­ogy and gene knock­out model an­i­mal pro­duc­tion and re­search. Its ser­vices ranges from the prepa­ra­tion of gene en­gi­neered an­i­mals to large-scale sup­ply of an­i­mal mod­els.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.